Newly recognized physiologic and pathophysiologic actions of the angiotensin-converting enzyme

Curr Hypertens Rep. 2004 Apr;6(2):124-8. doi: 10.1007/s11906-004-0087-4.

Abstract

Despite several decades of research into the renin-angiotensin system, new aspects of this endocrine system are elucidated every few years, expanding its role not only in hypertension but also in diabetes, oncology, and cardiology. In this review, we describe newly recognized physiologic actions of the angiotensin-converting enzyme (ACE). These include the role of local versus systemic ACE in maintaining blood pressure, the physiology of bradykinin accumulation during ACE inactivation, and the role of alternate "non-angiotensin" substrates and potential non-enzymatic properties of ACE.

Publication types

  • Review

MeSH terms

  • Angiotensin-Converting Enzyme Inhibitors / pharmacology
  • Animals
  • Blood Pressure / drug effects*
  • Bradykinin / drug effects
  • Bradykinin / physiology
  • Humans
  • Hypertension / drug therapy
  • Mice
  • Models, Animal
  • Peptidyl-Dipeptidase A / physiology*
  • Renin-Angiotensin System / drug effects*
  • Renin-Angiotensin System / physiology

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Peptidyl-Dipeptidase A
  • Bradykinin